[ Open Now ] 5 Micro Cap Stocks with Massive Upside Potential according to Top Wall Street Analysts

This is a must read [View it in your browser.]( [ws_editorsdesk.png] --------------------------------------------------------------- [Where is the Next Big "Pot Shot Moonshot" Opportunity Hiding?]( [Discover where the next major cannabis opportunity could be hiding.]( --------------------------------------------------------------- March 3, 2022 From the desk of Editor (Micro Cap Report) Dear Reader, We just identified 5 Micro Cap stocks that have above average price targets according to the firms listed below. Today’s report includes Analyst coverage from the following firms; Morgan Stanley, Leerink Partners, Barrington, H.C. Wainwright, and Truist Financial. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [The "Underground" Pot Stock No One is Talking About]( that the floodgates are opening on Cannabis Boom 2.0, the "smart money" is looking beyond N. American pot companies for the next outsized returns. Discover the under-the-radar pot producer with a plan to dominate the world's biggest cannabis market. (Hint: it's NOT the US or Canada) [Read the Full Story On The Next Big Cannabis Boom]( --------------------------------------------------------------- [Bolt Biotherapeutics, BOLT]( Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on [Bolt Biotherapeutics (BOLT)]( the Healthcare sector with a Hold rating and a price target of $ 11 (1 month ago). - Recent Price: $3.16 - Average Analyst Price Target: $25.67 (712.34%) - Market Cap: $117.82M [TipRanks.com]( also reports that [Bolt Biotherapeutics]( has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $25.67 . The target pricing ranges from a high forecast of $33.00 down to a low forecast of $11.00. [Bolt Biotherapeutics (BOLT)]( last closing price was $3.16 which would put the average price target at $25.67. Here are 3rd party ratings for [BOLT]( - TipRanks.com: Strong Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 39% (153 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- ["The Fastest Inflation Gain Since 1983..."]( you remember what mass inflation was like during the 80's? If so, then you probably realize the importance of protecting your wealth, livelihood, and EVERYTHING you've worked so hard for. [Click Here To See How Elite Investors Are Protecting Their Wealth in This Economy]( --------------------------------------------------------------- [ContraFect, CFRX]( Recent Analyst Action: Roanna Ruiz, analyst at Leerink Partners, reiterates coverage on [ContraFect (CFRX)]( the Healthcare sector with a Buy rating and a price target of $ 9 (1 week ago). - Recent Price: $3.34 - Average Analyst Price Target: $7.75 (132.04%) - Market Cap: $131.37M [TipRanks.com]( also reports that [ContraFect]( has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $7.75 . The target pricing ranges from a high forecast of $9.00 down to a low forecast of $6.50. [ContraFect (CFRX)]( last closing price was $3.34 which would put the average price target at $7.75. Here are 3rd party ratings for [CFRX]( - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: n/a, n/a [Click here for chart >>]( -------------------------------------------------------------------------- [Lincoln Edu, LINC]( Recent Analyst Action: Alexander Paris, analyst at Barrington, reiterates coverage on [Lincoln Edu (LINC)]( the Services sector with a Buy rating and a price target of $ 9.5 (2 days ago). - Recent Price: $7.85 - Average Analyst Price Target: $11.83 (50.70%) - Market Cap: $211.96M [TipRanks.com]( also reports that [Lincoln Edu]( has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $11.83 . The target pricing ranges from a high forecast of $16.00 down to a low forecast of $9.50. [Lincoln Edu (LINC)]( last closing price was $7.85 which would put the average price target at $11.83. Here are 3rd party ratings for [LINC]( - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Strong Buy, Bottom 10% (224 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [America's top futurist: Don't buy bitcoin - buy THIS instead]( One of America’s best connected tech forecasters recently revealed the name and ticker symbol of one of his top stock ideas for the next decade. It’s part of an new, trillion-dollar opportunity that he believes is much more important – and potentially more lucrative than bitcoin (or any cryptocurrency). [Get the details here.]( --------------------------------------------------------------- [Spectrum Pharmaceuticals, SPPI]( Recent Analyst Action: Edward White, analyst at H.C. Wainwright, reiterates coverage on [Spectrum Pharmaceuticals (SPPI)]( the Healthcare sector with a Buy rating and a price target of $ 10 (2 weeks ago). - Recent Price: $0.7175 - Average Analyst Price Target: $6.67 (829.62%) - Market Cap: $126.61M [TipRanks.com]( also reports that [Spectrum Pharmaceuticals]( has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $6.67 . The target pricing ranges from a high forecast of $10.00 down to a low forecast of $4.00. [Spectrum Pharmaceuticals (SPPI)]( last closing price was $0.7175 which would put the average price target at $6.67. Here are 3rd party ratings for [SPPI]( - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Bottom 37% (156 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- [Viking Therapeutics, VKTX]( Recent Analyst Action: Joon Lee, analyst at Truist Financial, reiterates coverage on [Viking Therapeutics (VKTX)]( the Healthcare sector with a Buy rating and a price target of $ 28 (3 weeks ago). - Recent Price: $3.25 - Average Analyst Price Target: $19.40 (496.92%) - Market Cap: $254.68M [TipRanks.com]( also reports that [Viking Therapeutics]( has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.40 . The target pricing ranges from a high forecast of $28.00 down to a low forecast of $10.00. [Viking Therapeutics (VKTX)]( last closing price was $3.25 which would put the average price target at $19.40. Here are 3rd party ratings for [VKTX]( - TipRanks.com: Strong Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 39% (153 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [WARNING: Is Record Inflation Signaling A Bigger Storm On The Horizon?]( prices are up 49.5%. Used cars prices are up 37.3%. And food is up 12.6%. And what FED Chairman Jerome Powell says could come next is even worse. And that's why protecting your wealth, and learning what's coming is SO important. [Show Me How To Safeguard My Wealth!]( --------------------------------------------------------------- And there you have it--5 Micro Cap Stocks that are getting attention from some of Wall Street Top Analysts. Sincerely, Editor, FinancialMarketMovers.com FinancialMarketMovers.com | PO Box 407, Mt. Mourne, NC 28123 This is email was sent to {EMAIL} as part of your free newsletter subscription, [click here to unsubscribe](. Copyright © 2021 FinancialMarketMovers.com All rights reserved. This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.